Results 21 to 30 of about 3,014 (182)
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study. [PDF]
OncologistBackground: Erdafitinib is approved for locally advanced/metastatic urothelial cancer (LA/mUC). As enfortumab vedotin (EV) plus pembrolizumab enters frontline management, outcomes with erdafitinib pre- and post-EV are clinically relevant but not ...
Jiang CY +34 more
europepmc +2 more sources
Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy
Frontiers in Immunology, 2023 The treatment of metastatic urothelial carcinoma has dramatically changed over the past decade with the approval of several therapies from multiple drug classes including immune checkpoint inhibitors, targeted therapies, and antibody drug conjugates ...
David J. Benjamin, Robert Hsu
doaj +1 more source
Understanding Postmarketing Requirements and Commitments for CYP3A-Mediated Drug-Drug Interactions: An Analysis of FDA-Approved Drugs From 2015 to 2024. [PDF]
Clin Transl SciABSTRACT Addressing knowledge gaps at drug approval through drug–drug interaction (DDI)‐related postmarketing requirements (PMRs) and commitments (PMCs) is essential for safe and effective use. This analysis reviewed CYP3A‐related PMRs and PMCs, the most evaluated enzyme in postmarketing studies, to characterize their scope.
Yu J +4 more
europepmc +2 more sources
Therapeutic Advances in Medical Oncology, 2021 Background: Erdafitinib is the first targeted therapy approved for the treatment of patients with metastatic urothelial carcinoma (mUC). Approval was based on a phase II single-arm trial that demonstrated significant activity of erdafitinib in patients ...
Fernando Sabino M. Monteiro +6 more
doaj +1 more source
, 2022 Background: Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, was shown to be clinically active and tolerable in patients with advanced urothelial carcinoma and prespecified FGFR alterations in the primary analysis of
Schinzari G.
core +4 more sources
, 2023 Purpose: On 12 April 2019, erdafitinib gained the first FDA approval as the second-line treatment for adult patients with locally advanced or metastatic urothelial cancer following progression during or after at least one previous line of platinum-based ...
Hui Guo (110581) +3 more
core +1 more source
, 2021 Objective: A robust, quick, and reliable ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) method for the quantification of erdafitinib in beagle dog plasma was developed and validated to evaluate the changes of posaconazole ...
Xiang-jun Qiu (11764286) +5 more
core +1 more source
Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
Clinical Medicine Insights: Oncology, 2022 The treatment landscape of metastatic urothelial cancer (mUC) remained unchanged for over 30 years until the approval of immune checkpoint inhibitors (ICIs) in 2016. Since then, several ICIs have been approved for the treatment of mUC.
David J Benjamin +2 more
doaj +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2022 A population pharmacokinetic (PK)–pharmacodynamic (PD) model was developed using data from 345 patients with cancer. The population PK‐PD model evaluated the effect of erdafitinib total and free plasma concentrations on serum phosphate concentrations ...
Anne‐Gaëlle Dosne +11 more
doaj +1 more source
Deep Contrastive Learning for High-Throughput Prediction of Drug Resistance Mutations from Sequences. [PDF]
Adv Sci (Weinh)This study presents DeepMutDTA, a deep learning framework aimed at predicting mutation‐induced changes in protein‐drug interactions and prioritizing variants potentially linked to drug resistance. Trained on large‐scale data, it incorporates SimSiam‐MuTF, a label‐aware contrastive fine‐tuning strategy that encourages separation between WT and MT ...
Hu X +7 more
europepmc +2 more sources